Biomarker analysis shows that treatment of ER+ breast cancer with capivasertib (360 mg or 480 mg twice a day) for 4.5 days effectively inhibits the phosphorylation of Akt targets including GSK3 and PRAS40 [224]. This evidence concerns the gene AKT1 and breast cancer.